Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
1.385 ^USD	-3.15%		-4.48%	-87.26%

08/05	Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	MT
08/05	Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05	AQ
Marinus Pharmaceuticals: Q1 Earnings Snapshot	08/05	AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck	08/05	PU
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	08/05	BU
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference	02/05	BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024	01/05	BU
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	15/04	BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	06/04	BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	28/03	AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review	27/03	BU
Marinus Pharmaceuticals: Q4 Earnings Snapshot	06/03	AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck	06/03	PU
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	06/03	BU
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences	21/02	BU
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	20/02	BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	17/02	BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update	05/01	AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	05/01	BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update	04/01	BU
Marinus Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	08/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Press Releases

Filters